SAMBA EU Femoropopliteal Trial

• ClinicalTrials.gov Identifier: NCT01139177
• Recruitment Status: Unknown
• First Posted: June 8, 2010
• Last Update Posted: June 8, 2010
• Sponsor: NovoStent Corporation
• Information provided by: NovoStent Corporation

Study Description

Brief Summary:

The primary objective of this study is to evaluate the safety and performance of the SAMBA Stent and Delivery System in the treatment of femoropopliteal lesions.

Condition or disease	Intervention/treatment	Phase
Peripheral Vascular Disease	Device: Stenting of atherosclerotic lesion(s)	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 39 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: SAMBA EU Femoropopliteal Trial
• Study Start Date: April 2009
• Estimated Primary Completion Date: September 2010
• Estimated Study Completion Date: September 2010

Arms and Interventions

Arm	Intervention/treatment
Experimental: Stent placement	Device: Stenting of atherosclerotic lesion(s); Stenting of atherosclerotic lesions post pre-dilatation of lesion(s); Other Name: SAMBA Stent and Delivery System

Outcome Measures

Primary Outcome Measures :

1. The primary safety endpoint is defined as freedom from all cause death, unplanned index limb amputation, and target lesion revascularization. [ Time Frame: through 30 days ]
2. The primary efficacy endpoint is defined as stent patency via Color Duplex Ultrasound (Peak Velocity Ratio ≤ 2.5). [ Time Frame: 3 months ]

Secondary Outcome Measures :

1. Clinically-Driven Target Lesion Revascularization (i.e., with documented preintervention evidence of at least 50% diameter stenosis (quantitative angiographic ≥ 50% or PSVR > 2.5). [ Time Frame: 12 months ]
2. Change in Rutherford Classification compared to pre-implant. [ Time Frame: 12 months ]
3. Stent Patency via Color Duplex Ultrasound (Peak Systolic Velocity Ratio ≤ 2.5). [ Time Frame: 12 months ]
4. Stent Fractures. [ Time Frame: 12 months ]

Eligibility Criteria

• Ages Eligible for Study: 21 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Screening

1. Patient must be ≥ 21 years of age with life expectancy > 1 year.
2. Symptomatic leg ischemia requiring treatment of the superficial femoral and/or popliteal artery (Rutherford category 2-4; claudication, rest pain).
3. Patient must be a suitable candidate for PTA and stenting.
4. Patient is willing and able to return to the site of the investigation at the specified study intervals and undergo follow-up requirements.
5. The patient or legal representative has provided written informed consent using a form that is reviewed and approved by the EC for the Clinical Site.

Pre-Intervention

1. Target lesion has ≥ 50% stenosis as demonstrated angiographically.
2. Lesion length ≤ 15 cm.
3. Reference vessel diameter of 5 to 6 mm.
4. Patient has at least 1 vessel run-off prior to treatment.

Exclusion Criteria:

Screening

1. The subject is pregnant or will become pregnant during the study or has any other condition that would preclude having x-rays. (Pre-menopausal women must have a negative pregnancy test within 7 days of the procedure.)
2. Patients who have experienced a cardiovascular accident (CVA) or a myocardial infarction (MI) within 3 months prior to the procedure.
3. Subject has had or plans to have a surgical or interventional procedure within 30 days before or after the implantation procedure of the SAMBA Stent.
4. Existing hemorrhagic disease or coagulation problems or inability to take dual anti-platelet therapy.
5. Contrast allergy that cannot be corrected with medication (e.g. steroids, etc.).
6. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment.
7. Patient is currently participating in another investigational drug or device study.

Pre-Intervention

1. Uncorrectable severe aorto-iliac occlusive disease or severe common femoral artery stenosis preventing access or limiting inflow (e.g., stenosis greater than 50%).
2. Uncorrectable occlusive disease limiting outflow (e.g., stenosis greater than 50%)
3. Patients with previous surgery in the target vessel or stent that will be closer than 2 cm to either edge of SAMBA Stent(s).
4. Lack of 1 cm of healthy vessel proximal to proximal target
5. Lack of popliteal reconstitution (at least 2 cm of normal distal popliteal).
6. Inability to cross the lesion with a guidewire.
7. More than 1 lesion in the same limb requiring treatment that will not be covered by continuous stenting.
8. Unsuccessful balloon pre-dilation (i.e., the residual stenosis is greater than 30%).

Contacts and Locations

Locations

Germany

Herz Zentrum Bad Krozingen

Bad Krozingen, Germany, D 79189

Herz-Zentrum Leipzig

Leipzig, Germany, D-04289

Sponsors and Collaborators

NovoStent Corporation

Investigators

• Principal Investigator: Dierk Scheinert, MD; Herz-Zentrum Leipzig

More Information

• Responsible Party: Earle Canty, VP RACAQA, NovoStent Corporation
• ClinicalTrials.gov Identifier: NCT01139177 History of Changes
• Other Study ID Numbers: 60-00857-01
• First Posted: June 8, 2010
• Last Update Posted: June 8, 2010
• Last Verified: June 2010

Keywords provided by NovoStent Corporation:

Peripheral vascular disease - SFA and popliteal arteries.

Additional relevant MeSH terms:

Vascular Diseases; Peripheral Vascular Diseases; Peripheral Arterial Disease; Cardiovascular Diseases; Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases